Ingrid Gafanhão's questions to HOOKIPA Pharma (HOOK) leadership • Q4 2020
Question
Ingrid Gafanhão of Kempen asked for an update on the Gilead partnership, specifically inquiring if any significant development milestones could be expected during the year.
Answer
CEO Joern Aldag confirmed that a milestone for the HIV program is expected around the middle of the year. This milestone is a 'request for development,' which signifies Gilead's commitment to advance the program toward clinical trials. He also noted that the HPV program is expected to move into the clinic late in the year or early the following year.